Thrombolysis and cardiac arrest

Area of Science:

• Cardiology
• Emergency Medicine
• Pharmacology

Background:

• Cardiac arrest (CA) frequently leads to death or irreversible organ damage.
• Coagulopathy post-CA impairs tissue perfusion, even with return of spontaneous circulation (ROSC), causing the no-reflow phenomenon.
• Thrombolysis is a potential intervention to address microcirculatory obstruction by dissolving blood clots.

Purpose of the Study:

• To evaluate the effectiveness of thrombolysis in improving clinical outcomes after cardiac arrest.
• To assess the impact of thrombolysis on survival rates and neurological status.
• To review evidence regarding thrombolysis's role in managing coagulopathy and the no-reflow phenomenon post-CA.

Main Methods:

• Review of clinical trials and evidence-based medicine (EBM) studies.
• Analysis of data on survival, hospital admissions, and neurological status.
• Examination of bleeding complications associated with thrombolysis.

Main Results:

• Previous studies suggested positive outcomes from thrombolysis, including improved survival and neurological function without significant bleeding.
• The pivotal TROICA trial did not confirm the expected benefits of thrombolysis.
• Thrombolysis is not widely recommended or used in clinical practice due to conflicting evidence and other factors.

Conclusions:

• Despite theoretical benefits in addressing coagulopathy and no-reflow after cardiac arrest, thrombolysis has not demonstrated consistent clinical efficacy.
• Concerns regarding efficacy, cost, and adverse effects limit the routine application of thrombolysis in cardiac arrest management.
• Further research may be needed to clarify the specific role, if any, of thrombolysis in selected cardiac arrest scenarios.